Inicio>>Signaling Pathways>> GPCR/G protein>> Urotensin Receptor>>Urotensin II, mouse acetate

Urotensin II, mouse acetate

Catalog No.GC62225

Urotensina II, acetato de ratÓn es un ligando endÓgeno para el receptor acoplado a proteÍna G huérfano GPR14 o SENR.

Products are for research use only. Not for human use. We do not sell to patients.

Urotensin II, mouse acetate Chemical Structure

Tamaño Precio Disponibilidad Cantidad
1 mg
135,00 $
Disponible
5 mg
540,00 $
Disponible
10 mg
855,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system[1].

Urotensin II is a somatostatin-like cyclic peptide which functions as an arterial vasocontrictor, vasodilator, and bronchoconstriction mediator[1]. Urotensin II (0.1 nmol, 0.3 nmol, and 3 nmol; intracerebroventricular administration) induces anxiogenic-like behaviors in the elevated plus maze test and the hole-board test in mice in a dose-dependent manner[1].

[1]. Matsumoto Y, et al. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett. 2004 Mar 25;358(2):99-102.

Reseñas

Review for Urotensin II, mouse acetate

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Urotensin II, mouse acetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.